| Date Checked | 2026-02-19 22:14:46 |
|---|---|
| Graham Number | (PB)21.75 vs (PE)36.41 |
| Over / Under Value Percentage | 133.24% vs 65.79% |
| Dividend Yield | 3.03% |
| Dividend Date | 2026-04-09 |
| Symbol | GSK |
| AssetType | Common Stock |
| Name | GlaxoSmithKline PLC ADR |
| Description | GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom. |
| CIK | 1131399 |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | DRUG MANUFACTURERS - GENERAL |
| Address | 79 NEW OXFORD STREET, LONDON, UNITED KINGDOM, WC1A 1DG |
| OfficialSite | https://www.gsk.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-12-31 |
| MarketCapitalization | 118251422000 |
| EBITDA | 13210000000 |
| PERatio | 15.59 |
| PEGRatio | 0.382 |
| BookValue | 5.56 |
| DividendPerShare | 0.66 |
| EPS | 3.78 |
| RevenuePerShareTTM | 16.13 |
| ProfitMargin | 0.175 |
| OperatingMarginTTM | 0.167 |
| ReturnOnAssetsTTM | 0.0978 |
| ReturnOnEquityTTM | 0.433 |
| RevenueTTM | 32667001000 |
| GrossProfitTTM | 23719999000 |
| DilutedEPSTTM | 3.78 |
| QuarterlyEarningsGrowthYOY | 0.551 |
| QuarterlyRevenueGrowthYOY | 0.062 |
| AnalystTargetPrice | 56.06 |
| AnalystRatingStrongBuy | 1 |
| AnalystRatingBuy | 1 |
| AnalystRatingHold | 5 |
| AnalystRatingSell | 1 |
| AnalystRatingStrongSell | 0 |
| TrailingPE | 15.59 |
| ForwardPE | 22.68 |
| PriceToSalesRatioTTM | 3.62 |
| PriceToBookRatio | 5.3 |
| EVToRevenue | 3.098 |
| EVToEBITDA | 8.52 |
| Beta | 0.272 |
| 52WeekHigh | 60.37 |
| 52WeekLow | 31.39 |
| 50DayMovingAverage | 50.72 |
| 200DayMovingAverage | 43.4 |
| SharesOutstanding | 2006642000 |
| SharesFloat | 3872264000 |
| PercentInsiders | 0.066 |
| PercentInstitutions | 19.146 |
| ExDividendDate | 2026-02-20 |
| etoro | 1 |
| dateChecked | 2026-02-19 22:14:46 |
| fresh | 1 |